Tag:

Merck

Latest Headlines

Latest Headlines

Sources: Merck negotiates huge production deal with Lupin

Merck is investing €80 million ($107.67 million) in a new plant in China to make treatments for diabetes and other conditions and to realize its aspirations there. But it appears it is looking to India as a way to cut production costs on some of its older products.

UPDATED: Safety concerns cloud odanacatib PhIII as Merck steps back from FDA filing

A growing buzz about potential safety issues has raised a cloud of doubt about Merck's osteoporosis drug odanacatib, which is likely to linger now that the pharma giant has released Phase III results and laid out plans for a delayed FDA filing.

UPDATED: Merck again shipping BCG cancer treatment but Sanofi still is not

When a shortage of BCG vaccine used to treat tuberculosis and bladder cancer developed two years ago because of serious problems at a Sanofi Pasteur plant, the FDA asked Merck to pick up the slack. But Merck has had supply issues that interrupted production that it is only now resolving.

Merck's Frazier disses tax inversion strategy, at least for Merck

Tax inversion deals--buying a controlling share in a sizable company to shave a corporate tax rate--are all the rage among pharma players. But to Ken Frazier, doing a mega deal just to pull off tax inversion doesn't make sense, at least not for Merck.

Lawsuits claiming Merck lied about mumps vaccine efficacy headed to trial

Two lawsuits claiming Merck lied about the efficacy of its mumps vaccine won't be going away anytime soon. A federal judge in Pennsylvania refused to dismiss the suits, filed by a pair of whistleblowers and a group of doctors and payers, and now, they're on their way to trial.

Judge: Merck must fight claims that it lied about mumps vaccine benefits

Merck tried to block two lawsuits claiming it lied about the efficacy of its mumps vaccine--but the pharma giant couldn't stop them. A federal judge in Pennsylvania refused to dismiss the lawsuits, filed by a pair of whistleblowers and a group of doctors and payers. Next stop: Trial.

Bristol-Myers socks Merck's brand-new Keytruda with PD-1 patent suit

Bristol-Myers Squibb is doing its best to rain on Merck & Co.'s immunotherapy parade. No sooner had Merck won FDA approval for its brand-new cancer drug Keytruda (pembrolizumab) than Bristol-Myers and its partner Ono Pharmaceutical slapped it with a patent-infringement lawsuit.

UPDATED: Merck's melanoma 'game-changer' Keytruda likely to bolster drug pricing debate

Analysts and doctors hailed the arrival of Merck's Keytruda, the first cancer drug in the U.S. to block the PD-1 pathway--a powerful new way to mobilize patients' immune systems to fight their disease. Then came this news: Merck said Keytruda (pembrolizumab) would cost $12,500 per patient per month, or $150,000 per year.

Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab

Merck has won the frenzied race to secure the first FDA approval for a new breed of cancer treatment, clearing the way for a U.S. launch and a scramble for dominance in a field expected to peak at nearly $35 billion a year.

Merck's new antibiotic hops on the FDA fast track

Merck has secured the FDA's fast-track designation for its latest antibiotic candidate, a mid-stage treatment for complicated infections.